No Interaction Expected
Quality of Evidence:
Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rifabutin is mainly metabolized by CYP3A4 and cholinesterase. Based on the results of the interaction study between tenofovir-DF and rifampicin, rifabutin is unlikely to impact tenofovir-DF to a large extent.
View all available interactions with
Tenofovir-DF (TDF) by clicking